Data also demonstrates that the stroke risk reduction device is as effective as oral anticoagulants for patients with atrial fibrillation following a cardiac ablation The trial met the primary safety ...

Boston Scientific, Inc. BSX recently announced receiving the FDA approval for the latest-generation WATCHMAN FLX Pro Left Atrial Appendage Closure (LAAC) Device. The latest device is intended to ...

New stroke risk reduction therapy with thromboresistant coating is designed to advance procedural performance and safety MARLBOROUGH, Mass., Sept. 6, 2023 /PRNewswire/ -- Boston Scientific Corporation ...

MINNEAPOLIS - It wasn’t an easy road to obtain FDA approval for Boston Scientific’s Watchman Left Atrial Appendage (LAA) Closure Device. The Marlborough, MA-based company’s device was rejected by FDA ...

Boston Scientific Corporation BSX recently gained FDA approval to expand the current-generation WATCHMAN FLX Left Atrial Appendage Closure (LAAC) Device’s instructions for use labeling. Per management ...

Boston Scientific has obtained an FDA green light for the latest version of its Watchman heart implant, designed to help lower the risk of stroke in patients with atrial fibrillation. Compared to its ...

After the FDA said last year it would keep a closer eye on the potential complications of a type of permanent heart plug designed to cut the risk of stroke, Boston Scientific has put forward ...

Data also demonstrates that the stroke risk reduction device is as effective as oral anticoagulants for patients with atrial fibrillation following a cardiac ablation MARLBOROUGH, Mass. and CHICAGO, ...

MARLBOROUGH, Mass., Sept. 6, 2023 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) today announced it has received U.S. Food and Drug Administration approval for the latest-generation ...

Boston Scientific’s fourth quarter results were met with a significant negative market reaction, despite meeting revenue ...

Boston Scientific (NYSE: BSX) is scheduled to report its Q2 2024 results on Wednesday, July 24. We expect the company to report revenues and earnings in line with the consensus estimates. A rise in ...